COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE UK

被引：0
|
作者：
Schlueter, M. [1 ]
Vega-Hernandez, G. [2 ]
Wojcik, R. [1 ]
机构：
[1] IMS Hlth, London, England
[2] Novo Nordisk Ltd, Gatwick, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1886
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB56
引用
收藏
页码：A675 / A675
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Hou, X.
    Wan, X.
    Li, Y.
    Ding, Y.
    Wu, B.
    VALUE IN HEALTH, 2019, 22 : S144 - S144
  • [22] Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
    Hou, Xingyun
    Wan, Xu
    Wu, Bin
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [23] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Ioannidis, Ioannis
    Tsimihodimos, Vasilis
    Diogo, Viana
    Karpouzos, George
    Papageorgiou, Giannis
    Kourlaba, Georgia
    CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 371 - 380
  • [24] Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
    Gu, Shuyan
    Mu, Yiming
    Zhai, Suodi
    Zeng, Yuhang
    Zhen, Xuemei
    Dong, Hengjin
    PLOS ONE, 2016, 11 (11):
  • [25] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    George Gourzoulidis
    Charalampos Tzanetakos
    Ioannis Ioannidis
    Vasilis Tsimihodimos
    Viana Diogo
    George Karpouzos
    Giannis Papageorgiou
    Georgia Kourlaba
    Clinical Drug Investigation, 2021, 41 : 371 - 380
  • [26] The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30kg/m2
    Dilla, Tatiana
    Alexiou, Dimitra
    Chatzitheofilou, Ismini
    Ayyub, Ruba
    Lowin, Julia
    Norrbacka, Kirsi
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (05) : 443 - 452
  • [27] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [28] THE COST-EFFECTIVENESS EVALUATION OF CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN MONOTHERAPY IN SPAIN
    Nielsen, A. T.
    Pitcher, A.
    Lovato, E.
    Schubert, A.
    Hemels, M.
    Neslusan, C.
    Gonzalez, B.
    VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
  • [29] EVALUATING SHORT-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE SETTING
    Fan, C. S.
    Zhong, J.
    Sun, F.
    Liu, F.
    VALUE IN HEALTH, 2013, 16 (03) : A162 - A163
  • [30] Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain
    Pinol, Carme
    Roze, Stephane
    Valentine, William
    Evers, Thomas
    GACETA SANITARIA, 2007, 21 (02) : 97 - 104
12345